Worldwide population prevalence and impact of sub‐diagnostic gastrointestinal symptoms
Alimentary Pharmacology & Therapeutics · 2024-04 · 59 (7) · 852-864
DOI: 10.1111/apt.17894 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, published online on 2024-02-04. Written by Olafur S Palsson and 10 co-authors. Institution: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. Major MEDLINE topics: Quality of Life, Gastrointestinal Diseases. Cited 25 times so far (Crossref); 17 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Danone Nutricia Research.
Abstract (original language)
Background
The Rome Foundation Global Epidemiology Study (RFGES) found that 40.3% of adults in 26 internet‐surveyed countries met Rome IV criteria for disorders of gut–brain interaction (DGBI). However, additional people not meeting DGBI criteria may also be burdened by frequent gastrointestinal symptoms.
Aims
To explore the prevalence and demographic distribution of sub‐diagnostic gastrointestinal symptoms, and the hypothesised associated effects on quality of life (QoL), life functioning and healthcare needs.
Methods
We analysed data from the RFGES survey, which included the Rome IV diagnostic questionnaire and QoL, psychological, work productivity and healthcare questions.
Results
Of the 50,033 people without a history of organic gastrointestinal disorders, 25.3% classified in the sub‐diagnostic group (no DGBI but one or more frequent gastrointestinal symptoms), 41.4% had DGBI and 33.4% had no frequent gastrointestinal symptoms (non‐GI group). Sub‐diagnostic prevalence in different world regions ranged from 22.2% (North America) to 30.5% (Middle East), was slightly higher among males than females and decreased with age. The sub‐diagnostic group was intermediate between the non‐GI and DGBI groups, and significantly different from both of them on QoL, anxiety, depression, somatisation, healthcare utilisation and life and work impairment.
Conclusions
One in four adults without organic gastrointestinal disorders or DGBI report frequent gastrointestinal symptoms. This sub‐diagnostic group has reduced QoL, greater psychological and non‐GI bodily symptoms, impaired work productivity and life activities and greater healthcare use compared to non‐GI individuals. This suggests that many in this sub‐diagnostic group might benefit from healthcare services or symptom self‐management advice.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium.
- University of North Carolina at Chapel Hill and CEO of the Rome Foundation, Raleigh, North Carolina, USA.
- Danone Nutricia Research, Gif-sur-Yvette, France.
- The Rome Foundation, Raleigh, North Carolina, USA.
- Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
ORCID profiles: Olafur S Palsson, Boris Le Nevé, Johannah Ruddy, Ami D Sperber
Funding
- Danone Nutricia Research
Cite
APA
Palsson, O. S., Tack, J., Drossman, D. A., Le Nevé, B., Quinquis, L., Hassouna, R., Ruddy, J., Morris, C. B., Sperber, A. D., Bangdiwala, S. I., & Simrén, M. (2024). Worldwide population prevalence and impact of sub‐diagnostic gastrointestinal symptoms. Alimentary Pharmacology & Therapeutics, 59(7), 852-864. https://doi.org/10.1111/apt.17894
Vancouver
Palsson OS, Tack J, Drossman DA, Le Nevé B, Quinquis L, Hassouna R, et al. Worldwide population prevalence and impact of sub‐diagnostic gastrointestinal symptoms. Alimentary Pharmacology & Therapeutics. 2024;59(7):852-864. doi:10.1111/apt.17894
BibTeX
@article{Palsson2024,
author = {Palsson, Olafur S and Tack, Jan and Drossman, Douglas A and Le Nevé, Boris and Quinquis, Laurent and Hassouna, Rim and Ruddy, Johannah and Morris, Carolyn B and Sperber, Ami D and Bangdiwala, Shrikant I and Simrén, Magnus},
title = {Worldwide population prevalence and impact of sub‐diagnostic gastrointestinal symptoms},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
volume = {59},
number = {7},
pages = {852--864},
doi = {10.1111/apt.17894}
}
EUVIMED